Table 1.
Demographics
| Adult | Pediatric | ||
| N=10 | N=25 | ||
| Site – n (%) | Cincinnati | 3 (30) | 6 (24) |
| Dallas | 2 (20) | 5 (20) | |
| Denver | 2 (20) | 7 (28) | |
| New York | 0 (0) | 3 (12) | |
| Washington, DC | 3 (30) | 4 (16) | |
| Age in Years | Mean (SD) | 26.0 ( 7.5) | 11.2 ( 1.9) |
| Median (Min – Max) | 22.5 (18 – 37) | 12 (8 – 14) | |
| Gender – n (%) | Female | 7 (70) | 9 (36) |
| Male | 3 (30) | 16 (64) | |
| Ethnicity – n (%) | Hispanic or Latino | 0 (0) | 6 (24) |
| Not Hispanic or Latino | 10 (100) | 19 (76) | |
| Primary Race – n (%) | Black | 10 (100) | 18 (72) |
| White | 0 (0) | 6 (24) | |
| Unknown | 0 (0) | 1 (4) | |
| Baseline Total Nasal Symptom | Mean (SD) | 0.43 (0.65) | 1.04 ( 1.06) |
| Score | Median (Min – Max) | 0 (0 – 2) | 1 (0 – 3) |
| Inhaled Corticosteroid Medication | 100 mcg Fluticasone daily | 0 (0) | 1 (4) |
| Equivalent– n (%) | 200 mcg Fluticasone daily | 1 (10) | 9 (36) |
| 500 mcg Fluticasone daily | 5 (50) | 9 (36) | |
| 500 mcg Fluticasone daily + LABA | 4 (40) | 6 (24) | |
| Allergic Rhinitis – n (%) | Has History of Rhinitis | 4 (40) | 12 (48) |
| Has Ongoing Rhinitis | 3 (30) | 9 (36) | |